Ascendis Pharma A (ASND) EBITDA Margin (2014 - 2026)
Ascendis Pharma A (ASND) posted EBITDA Margin of 66.33% for the quarter ended Jun 30, 2026, up 97.03 percentage points from -30.70% a year earlier and up 54.55 percentage points from the prior quarter.
Ascendis Pharma A (ASND) EBITDA Margin (2014 - 2026) Analysis & Trends
For the trailing twelve months through Jun 30, 2026, EBITDA Margin at Ascendis Pharma A was 27.03%, up 74.91 percentage points year-over-year; for the year ended Dec 31, 2025, it came in at -29.47%, up 59.98 percentage points from the prior year.
- Annual EBITDA Margin has increased for four consecutive years, with a five-year change of +4589.72 percentage points (years ended Dec 2020 to Dec 2025).
- In prior years, Ascendis Pharma A's EBITDA Margin was -89.44% in the year ended Dec 31, 2024 (+107.98 pp), -197.43% in the year ended Dec 31, 2023 (+865.33 pp), -1062.76% in the year ended Dec 31, 2022 (+4547.95 pp) and -5610.71% in the year ended Dec 31, 2021 (-991.52 pp).
- The figure for the quarter ended Jun 30, 2026 stands as the highest quarterly EBITDA Margin in data going back to the quarter ended Mar 31, 2014.
- On a year-over-year basis, EBITDA Margin has increased in each of the last five quarters, with an average year-over-year change of +96.99 percentage points over the last eight quarters.
- The strongest year-over-year quarter for EBITDA Margin in the past five years was the quarter ended Mar 31, 2022, with a gain of 14400.86 percentage points; the weakest was the quarter ended Sep 30, 2021, with a drop of 5592.43 percentage points.
- According to Business Quant data, EBITDA Margin for the three prior quarters was 11.77% (quarter ended Mar 31, 2026), 5.95% (quarter ended Dec 31, 2025) and 6.92% (quarter ended Sep 30, 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 35.95% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 39.16% |
| 10 | Ascendis Pharma A | 14.48 Bn | 10.74 Bn | 362.22 Mn | 66.33% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 66.33% |
| Mar 31, 2026 | 11.77% |
| Dec 31, 2025 | 5.95% |
| Sep 30, 2025 | 7.03% |
| Jun 30, 2025 | -30.78% |
| Mar 31, 2025 | -98.73% |
| Dec 31, 2024 | 2.79% |
| Sep 30, 2024 | -159.72% |
| Jun 30, 2024 | -357.99% |
| Mar 31, 2024 | -46.58% |
| Dec 31, 2023 | -22.97% |
| Sep 30, 2023 | -269.94% |
| Jun 30, 2023 | -287.37% |
| Mar 31, 2023 | -414.24% |
| Dec 31, 2022 | -623.47% |
| Sep 30, 2022 | -915.57% |
| Jun 30, 2022 | -2,232.18% |
| Mar 31, 2022 | -1,810.40% |
| Dec 31, 2021 | -2,211.70% |
| Sep 30, 2021 | -8,369.18% |
Ascendis Pharma A EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ASND&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "ASND", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=ASND&period=max&api_key=YOUR_API_KEY");
const data = await res.json();